Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
...Remember That Afternoon NR when They Filed IND with FDA
Its tough tough To get filled On AON @ Ask....
Get Lost Low Rent! When A gout Drug Is Kicking A$$ And Bucillamine Is Proven more Effective And More Potent! That Is Worthy News. And That Is What Pharmacutical Companies Take Stock In! Even though Colchicine Is In A Targeted Area being Used As A Covid Drug Trial (Greece) The Fact Remains. Anti Viral Anti Inflamation With A low cost Repurposed Drug Is The Path...
Aug.31.2020 When A Anti Viral Gout Drug With No FDA Approval Is Showing Stellar Results On Covid And Heart Disease! It Means when The CEO Says We Are Moving On With Big Pharmacutical Or With Out; It Means We Are Moving On)) https://www.prnewswire.com/news-releases/early-in-hospital-treatment-with-colchicine-reduces-the-odds-of-future-cardiovascular-problems-by-48-in-people-who-have-just-survived-a-heart-attack-301120646.html
Penny still looking To Get A Position. Just Dont Cry When They Halt The Stock For News And You Got Nothing In Your Hand But A little Vienna Sausage...
Just out: Australia.Netherlands. Gout Drug Stops Heart Disease. Let Them Say What They Want about This Anti Viral Anti Inflamation Gout Drug that Kicks A$$ And Is A Lot Like Bucillamine Except Bucillamine Is More Potent....It Means We Have Interest We Have Tire Kickers And As The CEO Said We Are Going To Trials!! Todays News: https://www.hospitalhealth.com.au/content/clinical-services/news/gout-treatment-halts-coronary-disease-progression-41107292#axzz6XSZghtWy
Its too Early In The Day After Holiday On Both Sides Of The Border....He Likes Doing It At 1:00 Pm Etc In The After Noon As Well; People Have Forgotten that...Getting To Used To The Morning News.
Market Watch Has 2.36 Billion OS @ 1.63 Billion Float...But of Course they Are Always Lagging Behind current Numbers)
1 Hour Ago: Texas Gov Announces Disaster Declaration For All Of Texas: https://www-ksat-com.cdn.ampproject.org/v/s/www.ksat.com/news/texas/2020/09/07/gov-abbott-extends-statewide-covid-19-disaster-declaration/?amp_js_v=a3&_gsa=1&outputType=amp&usqp=mq331AQFKAGwASA%3D#aoh=15995268957847&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.ksat.com%2Fnews%2Ftexas%2F2020%2F09%2F07%2Fgov-abbott-extends-statewide-covid-19-disaster-declaration%2F
Gway. As Always You Offer Nothing!! Comparing Colchicine Vs Bucillamine Is Apple And Oranges; Bucillamine Is Way More Potent And Colchicine Has Crokus Flower In It. But Comparing the 2 Gout Drugs With Colchicine Getting A License Deal In Greece By A Large Pharmaceutical Company And Showing Sucess Is Worth Reporting. Even Though Colchicine Has No FDA Approval Like Revive...Thanxs For Listening As Always.
Their Strips Sounds Like Suboxene Strips. The #1 Seller To Curve Opiate Addictions....
Sept 4,2020 "Drug Repurposing, Momentum Grows As Data BOOMS" https://www-technologynetworks-com.cdn.ampproject.org/v/s/www.technologynetworks.com/drug-discovery/articles/amp/drug-repurposing-could-open-the-door-to-new-therapies-339398?amp_js_v=a3&_gsa=1&usqp=mq331AQFKAGwASA%3D#aoh=15995067259729&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.technologynetworks.com%2Fdrug-discovery%2Farticles%2Fdrug-repurposing-could-open-the-door-to-new-therapies-339398
Ceo Addresed A Sponsor In Barringtons Interview When Barrington Asked About Tire Kickers And Barrington Went on to say Can You Talk About This. CE0 Response was "Obviously Their Are Pharmaceutical Companies Looking For Strategic Partners; But They Could Go The Route Of Government Funding Or They Could Do it Alone....Read In between The Lines. 3 Options. Wich One Is The Better Deal And If We Go The Route Of The Sponsor Perhaps Their Deal Is Not Sweet Enough Yet! That Interview Is A Week Old....
Nice Link Norm. Bucillamine =16× Anti Viral And We Are At The Top Of The LIST. https://www.raps.org/news-and-articles/news-articles/2020/3/covid-19-therapeutics-tracker
Deadly Rail Road Strike Lead Path To Labor Day https://www.history.com/news/labor-day-pullman-railway-strike-origins
"A Tell" In Interview With Barrington The CEO Is Asked About Getting His Tires Kicked; His Response Spanned Three Scenerios. (In order) CEO "Obviously some Big Pharmaceuticals Are Looking For Strategic Partnerships" "Their Is Regulatory Agencies For Funding" "Or We Can kick Start It on Our Own From The 6 Million In a bank"....He Ended That with Stateing "Starting Trials Quickly is Foremost".....My Take Away Is He Is Playing Poker and So Our The potential Suitors At The Table. He Just Gave 3 Scenerios How He Is Going To Start Trials So If Your At The Table and You Our A Pharmacutical Company; Make The Bet Or Fold!! Because We Are Moving On.
Point being A Greek Pharmetucal Company Is Paying For The Study. A Drug Close To Bucillamine But Bucillamine Is More Potent: ATHENS - The Greek pharmaceutical company ELPEN is funding GRECCO-19, a clinical study which researches the active substance colchicine as a possible response treatment for the COVID-19 pandemic, the company said in a statement.
The results of this research against the coronavirus will signal a new day for Greece, but also for the international community, it underlined. "ELPEN is significantly reinforcing and supporting this difficult battle, proving in practice its steady and timeless commitment to the value of research. With deep faith in the scientific community of our country, the company supports this very important research effort," it stated.
ELPEN is funding the clinical study named GRECCO-19 concerning a treatment by the active ingredient colchicine. As it explained, the aim of this study is to treat and prevent complications and the development of COVID-19 disease, especially in patients with cardiovascular problems. This specific research is a Greek initiative, carried out by both Greek and foreign distinguished scientists. The GRECCO-19 study involves physicians from various specialties (Cardiologists, Pulmonologists, Infectologists) from university clinics and private hospital centers. The sponsor of the study is the Hellenic Rhythmological Society.
The study is being conducted at 24 research centers throughout Greece. The study aim the inclusion of 180 patients, 100 of whom have already been enrolled
Aug 30.2020 "Most Current News On Colchicine"; A Gout Drug Being Tested In Greece To Fight Covid 19 ( bucillamine Has Been Proven More Effective Than Colchicine With Data From Trials) https://cardiology2.com/early-in-hospital-treatment-with-colchicine-reduces-the-odds-of-future-cardiovascular-problems-by-48-in-people-who-have-just-survived-a-heart-attack/
OT: FDA Rejects My Pillow Guy. Will Not Even Allow It to Be Marketed As A Diet Supplement. FDA rejects oleandrin, an unproven coronavirus therapeutic pushed by MyPillow CEO, as a dietary supplement ingredient
By Jen Christensen and Jamie Gumbrecht, CNN
(CNN)The US Food and Drug Administration has rejected a submission from Phoenix Biotechnology Inc. to market oleandrin as a dietary supplement ingredient, citing "significant concerns" about the safety evidence the company presented.
Bloomberg: 23 Hours Ago: Ex FDA Director Under Trump; S.Gottleib Says 20% Of Americans Will Have Covid 19 By End Of Year! No Vaccine. Theraputics Is The Only Hope: https://www-bloomberg-com.cdn.ampproject.org/v/s/www.bloomberg.com/amp/news/articles/2020-09-06/virus-fatigue-is-risk-as-u-s-heads-into-fall-ex-fda-head-says?amp_js_v=a3&_gsa=1&usqp=mq331AQFKAGwASA%3D#aoh=15994940183552&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2020-09-06%2Fvirus-fatigue-is-risk-as-u-s-heads-into-fall-ex-fda-head-says
How to Grow Supreme Cannabis :https://www.theglobeandmail.com/investing/markets/stocks/FIRE-T/pressreleases/4352608£;
Covid 19 Long Term Effects: "Heart & Lungs" So You Survive Covid 19; How Long Do You Survive After Recovery If Your Heart And Lungs Have Been Severely Damaged...Mayo Clinic Aug18.2020 Heart & Lung Damage:https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-long-term-effects/art-20490351
I know!!! I wonder If Their Is Anyone That Doesnt Get It...The Small Trials In Greece That Has Started On Colchicine Is Having Huge Sucess Is A Win Win Situation For Bucillamine. Two Drugs That Are Both Anti Viral Gout Drugs Except Bucillamine Is More Potent And Newer (30) Years And Colchicine Has been Around For Ever....The DD Is Out Their, Do Your DD On This Folks "Your Going To Like What You Find" And The Fact It Is A Greece Study Tells Me It Is A Common Sense Trial To Beat Covid...Who Is Smarter Than The Greeks!!
Fred. Last time I was Here The Float Was 30 Million. Whats it up to Today Pal....
"Sea Weed Extract Outperforms Therapeutic Remdesiver In Fighting Covid 19" https://www-labroots-com.cdn.ampproject.org/v/s/www.labroots.com/trending/drug-discovery-and-development/18231/seaweed-extract-outperforms-remdesivir-blocking-covid-19/amp?amp_js_v=a3&_gsa=1&usqp=mq331AQFKAGwASA%3D#aoh=15994398897386&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.labroots.com%2Ftrending%2Fdrug-discovery-and-development%2F18231%2Fseaweed-extract-outperforms-remdesivir-blocking-covid-19
Bucillamine VS Colchicine
Revive Therapeutics Announces Positive Final Results from Its Phase 2 Study for the Treatment of Acute Gout Flares
A company focused on commercializing treatments for gout, and rare diseases such as Cystinuria, Wilson's disease and Rett syndrome, today announced positive final results from its phase 2a proof-of-concept clinical study of REV-002 (Bucillamine), an oral anti-inflammatory agent, for the treatment of acute gout flares.
Bucillamine was as good or better as compared to Colchicine, a gout drug in the U.S. with reported sales of $688 million for the 12 months ended August 2014 according to IMS Health. This early validation paves the way for a Phase 2b clinical study, which would be used as part of the new drug application to the FDA to seek approval of Bucillamine for the treatment of acute gout flares in the U.S."
The objective of the Phase 2a study was to evaluate the safety and tolerability, and the efficacy of two regimens of oral Bucillamine over seven days of treatment compared with Colchicine (Colcrys®) in the treatment of subjects with severe gout flare attack. The primary efficacy endpoint is the proportion of patients who responded to treatment defined as a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose without using rescue drug.
The final primary endpoint results from the Phase 2a study from a total of 74 subjects that had completed the seven-day treatment period are as follows:
In Arm A (oral Bucillamine - total of 900mg over 7 days), 55% (12/22 subjects) had a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose without using rescue drug;
In Arm B (oral Bucillamine - total of 1,800mg over 7 days), 46% (11/24 subjects) had a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose without using rescue drug;
In Arm C, the active comparator arm, (oral Colchicine - 1.8mg over 1 hour), 46% (13/28 subjects) had a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose without using rescue drug; and
Bucillamine was well tolerated and there were no serious adverse events reported in subjects taking Bucillamine.
"Bucillamine for the treatment of acute gout flares has a clear pathway to regulatory approval in the U.S., based on previously approved drugs by the FDA for this indication," said Dr. Lee Simon, senior clinical and regulatory affairs advisory to Revive. "These exploratory results reported above demonstrate that Bucillamine has a signal of efficacy similar to that observed with the comparator drug, Colchicine (Colcrys®), in this clinical study, which has been previously approved for this indication in the U.S. As a result, Revive is actively planning a potentially pivotal Phase 2b, adequate and well-controlled, multicenter, double blinded, placebo controlled trial. It is important to note, that in the U.S., regulatory approval requires a drug to be superior to placebo in the statistical analysis and to demonstrate this difference from placebo is clinically relevant in two replicate studies."
About the Phase 2a Proof-of-Concept Study
The Phase 2a study is an open-label, multicenter, active-controlled, parallel-group clinical trial designed to evaluate the safety and efficacy of two arms of Bucillamine 100mg tablet compared with the active comparator Colchicine (dosed acutely using the FDA-approved regimen) in the treatment of subjects with acute gout flares over a seven-day treatment period. A total of 20 clinical sites in the United States participated in the study and a total of 74 subjects who are confirmed with a qualifying severe gout flare attack was randomized into the study. Subjects were randomized in a 1:1:1 allocation ratio to either Arm A (oral Bucillamine - total of 900mg), Arm B (oral Bucillamine - total of 1,800mg) or Arm C (oral Colchicine - total of 1.8mg) over a seven-day treatment period.
The primary efficacy endpoint is the proportion of patients who responded to treatment. Treatment responders are defined as a ≥ 50% reduction in target joint pain score from baseline at 72 hours post-dose without using rescue drug. The target joint pain score is an 11-point Pain Intensity Numeric Rating Scale (PI-NRS) used to assess joint pain intensity while experiencing a gout flare on a scale from 0 (no pain) to 10 (worst possible pain). The PI-NRS is completed using a diary where the subject is required to circle the most appropriate number that best describe their level of pain in the identified target joint during specific time points.
About Gout
There were 14.3 million diagnosed prevalent cases of chronic gout in the major pharmaceutical markets in 2012, which is forecast to increase to 17.7 million by 2021 (Source: Decision Resources 2012). Gout in the U.S. affects approximately 8.3 million (~3.9%) of American adults (Source: Arthritis Rheum. 2011 Oct; 63(10):3136-41). It is estimated that the gout disease treatment market value will increase from $989 million in 2013 to $2.28 billion by 2018 (Source: GlobalData 2014). Gout is a painful disorder caused by elevated serum uric acid (sUA) in the body due to under excretion of uric acid and/or over production of uric acid. Most patients on the most commonly employed regimens for uric acid lowering fail to achieve a satisfactory serum urate level. Poor control of gout can lead to acute attacks of severe pain, and chronic joint damage and impairment of health related quality of life. Accordingly, there are needs in the market for new therapies to control gouty inflammation and hyperuricemia.
Although gout is a treatable condition, there are limited treatment options, many of which have adverse side effects. Drug treatment for gout includes anti-inflammatory agents (non-steroidal anti-inflammatories (NSAIDs), corticosteroids, Colchicine) and serum urate-lowering therapies, which work by lowering body stores of uric acid. Treatment of gouty inflammation is complicated by the fact that gout patients have a high incidence of cardiovascular and metabolic comorbidities. Common comorbidities include hypertension (70-80%), coronary artery disease (>30-40%), chronic kidney disease (~30-50%), diabetes (~25-40%), gastrointestinal tract diseases, and congestive heart failure (Source: Keenan, RT et. al., Prevalence of contraindications and prescription of pharmacologic therapies for gout. Am. J. Med. 2011, 124: 155-163). Managing patients with these comorbidities is challenging because the majority of them have contraindication for one or more first-line approved medications to treat acute gout. Current drug therapy limitations include: 90% of gout patients having at least one contraindication to NSAIDs and glucocorticoids; 50% to 66% having at least one contraindication to Colchicine. Moreover, corticosteroids can cause hypertension and worsening of blood sugar, and NSAIDs have substantial renal and cardiovascular toxicity.
About REV-002 (Bucillamine)
REV-002 (Bucillamine) is being developed by Revive as a potential new treatment for acute gout flares. Bucillamine is a disease-modifying anti-rheumatic drug, which is prescribed for rheumatoid arthritis in Japan and South Korea.
About Revive Therapeutics Ltd.
WAKE UP CALL FROM GREECE: The medication, called colchicine, is an anti-inflammatory taken as a pill. It's long been prescribed for gout, a form of arthritis, and its history goes back centuries. The drug was first sourced from the autumn crocus flower.
Doctors also sometimes use colchicine to treat pericarditis, where the sac around the heart becomes inflamed.
Now, a team of Greek researchers reporting Wednesday in JAMA Network Open said their small trial suggests colchicine may indeed help curb severe COVID-19.
The trial involved 105 Greek patients hospitalized in July with COVID-19. Besides receiving standard antibiotics and antivirals (but not remdesivir), half of the participants got daily doses of colchicine for up to three weeks, while the other half did not.
The results "suggest a significant clinical benefit from colchicine in patients hospitalized with COVID-19," according to the team led by Dr. Spyridon Deftereos, a cardiologist at Attikon Hospital in Attiki, Greece.
Specifically, while the condition of seven of 50 patients who didn't get colchicine "clinically deteriorated" to a severe stage (for example, requiring mechanical ventilation to survive), this was true for just one of the 55 patients who did receive colchicine, the researchers said.
Writing in a journal editorial, a group of U.S. physicians agreed that the study has limits, but applauded the Greek team for "showing us that an old drug may still have new life."
Dr. Amir Rabbani, a cardiologist at the University of California, Los Angeles, and colleagues stressed in the editorial that the study size was too small to offer a definitive statement on whether colchicine should be used routinely against COVID-19.
But they said that its effects on certain blood markers of heart function—as observed in the new study—suggest that colchicine has anti-inflammatory and anti-clotting effects that could help limit the cardiovascular damage wreaked by COVID-19.
Larger trial needed—and it's on the way
Dr. Rajiv Bahl is an emergency medicine physician in Orlando, Fla., who's seen the ravages of severe COVID-19 in patients firsthand. Reading over the Greek findings, he noted that colchicine "has also been used to prevent heart conditions such as pericarditis and other inflammatory conditions affecting the body."
Still, the new study is too small, so although it "does show some early promise, future studies need to be conducted before we can incorporate colchicine as an extensively used medication to help combat COVID-19," Bahl said.
That trial is already underway.
Really Penny World! ..Another Guy Out Of Position!! Right Place Right Time But what Good Is It...When You Dont Have The Gutz To Pull The Trigger!...
Getting Nervous Fred? No Position Yet! You Should Be Nervous. Just the Fact The Greeks Are Having Huge Success With A Gout Drug Fighting covid opens up Ones Vision; To See The Road Ahead Before The Masses...
What's the float up to Fred since they Are Dilluting?. I see were you came to Revive Board! Did u come to Revive Board because they Have A low float!
I owned Gilead Months ago. I bought it for its Theraputic Remedisiver. But when China kicked it out of Trials I Sold It. But That didn't stop It From U.S Trials In Wich The U.S Government Bought up The supply. It Has done poorly in U.S Trials And Their Are Reports From Scientists That Say It Is No Better Than Sea Weed Extract. Remedisiver Is $3.200.00 A dose and it Comes in IV Liquid Dossing. I Have No Ideal what U.S Paid But Obviously covid Is No Joke To Government; Because for them To Make Such A Reach For Remedisiver Shows You How Desperate The Situation Is. Again!! The FDA Made Revive Do the Expanded Trials on Bucillamine To Include All Age Groups. It Has 30 Years of Safety It Will Be much Less Than Remedisiver And it Works!! The Data On it clearing up pneumonia Is Amazing As you Know. But when we are In Trials imo It will Do wonders for Heart Disease Just As The Trials in Greece Are Showing For Their Repurposed Gout Drug...I have A lot Of Respect For Greece. when They Say Their Gout Drug Is Beating Covid I BELIEVE them. Why Would I BUY Into U.S Government Buying into Remedisiver When Countless 3rd Parties And Hospitals Say It Is Junk!
Marijuana oil vape pens have taken a commanding lead as the most popular “Cannabis 2.0” product in three key Canadian provinces, capturing more market share than other refined cannabis merchandise such as edibles, beverages, concentrated extracts and topicals combined during the first six months those items have been available in Canada.
New point-of-sale data collected by Seattle data analytics firm Headset shows that vape pen sales earned 16% of cannabis market share in Alberta this June, 13.4% in British Columbia, and 15.1% in Ontario.
The vast majority of market share is still held by “Cannabis 1.0” products – chiefly dried in flower or pre-rolled joints – which have been available since the outset of Canada’s adult-use legalization in October 2018.
“Cannabis 2.0” products started their slow rollout in mid-December and have been available in greater quantities since then.
Headset’s data shows that in Ontario, vape pen market share actually exceeded that of pre-rolls in February.
That trend continued through June, when pre-rolls comprised 12.5% of Ontario market share compared with 15.1% for vapes.
Ontario’s cannabis store regulator will double the number of stores it licenses per month, signaling faster growth on the horizon for Canada’s largest adult-use marijuana market.
In a late Tuesday announcement, the Alcohol and Gaming Commission of Ontario (AGCO) said it had issued 164 store licenses to date, with 150 stores open.
“At the government’s direction, the AGCO is now moving to double the pace of store authorizations this fall,” according to the agency’s announcement.
“The AGCO will soon contact all affected retail store applicants directly to advise them of any change to the timing of the issuance of their store authorizations.”
Beyond specifying “this fall,” the AGCO announcement did not make clear exactly when the increased pace of licensing will take effect.
“I think it still remains to be seen whether or not that doubling applies to September,” said Omar Yar Khan, national cannabis lead with Toronto consultancy Hill+Knowlton. “I think it might, but if not, I suspect it’ll definitely apply to October.”
AGCO had previously committed to authorizing approximately 20 new stores per month, meaning roughly 40 stores should be licensed each month under the new directive.
“I think that there is an opportunity, and I think there is an appetite within the sector, to see that cap lifted even further, perhaps to 75 (store authorizations) a month or even 100 a month,” Khan told Marijuana Business Daily.
“The government will need to work with OCS as they work to build up their warehousing capacity,” Khan added.
“But I think folks within the industry and folks who are waiting on their applications would be happy to hear that there is a plan in place to increase the (store) rollout in a responsible way.”
Ontario continues to lag behind other Canadian provinces in opening licensed cannabis stores.
With 164 adult-use cannabis store licenses, Ontario, with a population of 14.7 million people, offers roughly 1.1 cannabis store licenses per 100,000 people.
In contrast, the province of Alberta leads the market in terms of cannabis stores per capita, with 517 licenses to date or approximately 11.7 licenses per 100,000 people.
Retail sales figures show those raw store numbers are driving sales of regulated marijuana in Canada.
In June, regulated cannabis sales in Alberta were worth CA$46.7 million, a close second to Ontario’s CA$48.9 million in sales despite Alberta’s much smaller population.
Related Stories
Oklahoma group abandons effort to legalize adult-use cannabis
MA rules changes would allow marijuana delivery from wholesalers
US House to take up cannabis descheduling bill week of Sept. 21
Leave a Comment
This site uses cookies as described in our Cooki
COVID-19 is engulfing prisons like San Quentin and it shows how letting the virus spread unchecked may only accelerate the death count and prolong the illness for those who manage to survive it
Sarah Al-Arshani
Sep 4, 2020, 11:23 PM
SAN QUENTIN
A view of a new emergency care facility that was erected to treat inmates infected with COVID-19 at San Quentin State Prison on July 08, 2020 in San Quentin, California. Justin Sullivan/Getty Images
The coronavirus has run rampant in prisons, especially San Quentin State Prison in the Bay Area, and the unchecked spread may suggest that herd immunity without a vaccine is highly unlikely, The Los Angeles Times reported.
At least 2,200 cases have been reported out of the 3,260 people at the facility, with 25 deaths.
The death rate is equivalent to about 767 people dying out of every 100,000 people, which if applied to the entire US would mean 2.5 million deaths.
Herd immunity for COVID-19 requires immunity from 40% to 70% of the population, that means at least 32,500,000 people have to be immune.
Only 1.5% of the US has tested positive for coronavirus so far.
Of the more than 5 million cases, over 164,000 have died.
Visit Business Insider's homepage for more stories.
The coronavirus has run rampant in prisons, especially San Quentin, where, as of Monday, 2,200 cases had been reported out of the 3,260 people at the facility; there have been 25 reported deaths.
The Los Angeles Times reported that the unchecked spread of the coronavirus in San Quentin mirrors how some proposed we deal with the virus, by allowing as many members of the population to catch it for the sake of creating herd immunity.
However, while more than two-thirds of the prison population may have caught the virus, the spread has only meant prolonged illness and unnecessary death, the LA Times said.
The facility's death rate is equivalent to about 767 people dying out of every 100,000 people, the LA Times reported. By contrast, the death rate in the US as a whole is around 49.5 people for every 100,000. As of Tuesday, more than 164,000 people have died from COVID-19 in the US and over 5 million have been infected.
If the death rate from San Quentin was to be mirrored nationally it would equate to 2.5 million people dying from COVID-19.
Michael Kirkpatrick a former inmate who was released and tested positive for the virus told the LA Times that only about five cells in his tier of 50 cells didn't have people who were infected with the virus.
"You couldn't help but get it — you're staying in a place with no ventilation," he told the LA Times.
A high death rate is a major consequence to polices that support an unchecked spread to try and reach herd immunity, which is when a large enough percentage of a population is immune to a pathogen so that it cannot spread widely. In order for there to be herd immunity somewhere between 40% to 70% of the population would need to be immune to the coronavirus for it to be the case, Business Insider previously reported.
Only 5,139,920 have been infected across the US, which is only 1.5% of the population. In order to get anywhere close to heard immunity at least 132,500,000 people have to be immune to the virus, which means they have to be exposed.
Dr. Anthony Fauci, the US government's top infectious diseases expert, has said that the rate of exposure should not just come from people being infected and recovering but also vaccinations, the LA Times reported.
The situation playing out in prison isn't the only indicator that herd immunity may not be achieved anytime soon, especially without a vaccine.
A major Spanish study last month found that antibodies to the coronavirus disappeared after just a few weeks in some patients, Business Insider previously reported. The study found that only 5% of those tested across Spain maintained antibodies to the virus and that 4% of people who had tested positive for coronavirus antibodies in the first round of testing didn't test positive for the antibodies a week later.
NOW WATCH: Popular Videos from Insider Inc.
Do you have a personal experience with the coronavirus you'd like to share? Or a tip on how your town or community is handling the pandemic? Please email covidtips@businessinsider.com and tell us your story.
Get the latest coronavirus business & economic impact analysis from Business Insider Intelligence on how COVID-19 is affecting industries.
Its huge News when A Anti Viral Anti Inflammatory Gout Drug Is kicking A$$ In Greece. During Their Study On Gout Drug Colchicine They Also Realized besides A covid Fighter it Fights Heart Disease. #1 KilleR . Years Ago Bucillamine And Colchicine Went Head to Head. Bucillamine Is Stronger And more Affective. I Have More Faith In The Greeks When They Say The Gout Drug Works vs The U.S Media That Touted Gileads/Remedisiver That Has Been Proven To Be No Better Than Sea Weed Extract....Colchicine Gout Drug Is A Europe Drug That Is Being used In Greece Trials To Treat Covid.
CANADIAN CANNABIS STOCKS WILL CRUSH EARNINGS EXPECTATIONS: https://www-fool-com.cdn.ampproject.org/v/s/www.fool.com/amp/investing/2020/07/23/3-reasons-canadian-pot-stocks-could-crush-earnings.aspx?amp_js_v=a3&_gsa=1&usqp=mq331AQFKAGwASA%3D#aoh=15993558360932&referrer=https%3A%2F%2Fwww.google.com&_tf=From%20%251%24s&share=https%3A%2F%2Fwww.fool.com%2Finvesting%2F2020%2F07%2F23%2F3-reasons-canadian-pot-stocks-could-crush-earnings.aspx
If you go to Investorshub most Read Messages and click on the "last Hour" We Are #4. Considering very little posting today That Is Unusual To Say The Least! ..It Doesnt Mean They Come A Buying Tuesday But What It Does Mean Is When We Go GREEN and Start Moving Up! They Will Come ROLLING In!!...Because The Masses Don't Come A Running Until A Major Move Up)) And REVIVE IS On Major WATCH LIST! https://investorshub.advfn.com/boards/most_read.aspx?p=h
So The Greeks Are Fighting Covid With Colchicine. A Gout Drug. Tons Of Articles On It. What Is Interesting Bucillamine Has Been Proven Better Than Colchicine. The Greeks Like The Colchicine And If You Are The FDA or A Private Pharmaceutical This Should Make You Sit Up In Your Chair....Colchicine Sucess= Bucillamine Beats Covid. The Greeks Like The Pill Form And Low Cost Of Colchicine and they Like The Way It Wipes Out Pnemonia And Reduces Heart Swelling.
Now, a team of Greek researchers reporting Wednesday in JAMA Network Open said their small trial suggests colchicine may indeed help curb severe COVID-19. The trial involved 105 Greek patients hospitalized in April with COVID-19.Aug 24, 2020
Medical Xpress › news › 2020-...
In early trial, an ancient drug shows promise against severe COVID-19 - Medical Xpress